Saturday, August 22, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Rush to Establish Content-Authenticity Standards Amid Leadership Shakeups and Sustained Capex
Within days of each other in mid-August 2026, Google, Anthropic, and Spotify moved to formalize AI content watermarking and labeling policies, signaling an industry-wide push toward self-governed provenance standards as generative AI output floods consumer platforms. The shift coincides with executive turnover at OpenAI (Brad Lightcap's departure) and Meta's public AI manifesto, all set against continued heavy AI infrastructure capital expenditure and finance-sector moves (e.g., Wall Street paying for algorithmic edges on social signals) that underscore AI's deepening entanglement with capital markets.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,977
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,977 facts checked against source5,242 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 11, 2026

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

View original at globenewswire.com
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • TPST-2003 represents one of the largest datasets evaluating a CD19/BCMA dual-targeting CAR-T therapy

    60% confidence

  • The parallel-structure dual-targeting CAR architecture of TPST-2003 is truly innovative

    60% confidence

  • Tempest plans to present the results of the REDEEM-1 trial and updated results from the IIT at a scientific meeting later this year

    60% confidence

  • A total of 36 patients with rrMM had received one infusion of TPST-2003 as of January 31, 2026, including 24 patients in IIT and 12 patients in REDEEM-1

    60% confidence

  • All activities other than long-term stability testing planned to be complete in Q3 2026

    60% confidence

  • The potential to treat patients with extramedullary disease (EMD) and patients who have previously received a BCMA-targeting CAR-T is particularly exciting

    60% confidence

  • The recent positive results from the ongoing REDEEM-1 trial position TPST-2003 as a potential class-leading therapy for rrMM

    60% confidence

  • The parallel-structure dual-targeting CAR architecture of TPST-2003 is truly innovative

    60% confidence

  • TPST-2003 has the potential to treat patients with extramedullary disease (EMD) and patients who have previously received a BCMA-targeting CAR-T

    60% confidence

  • All activities other than long-term stability testing planned to be complete in Q3 2026 to support potential IND filing in Q4 2026

    60% confidence

  • This represents one of the largest datasets evaluating a CD19/BCMA dual-targeting CAR-T therapy

    60% confidence

  • The recent positive results from the ongoing REDEEM-1 trial position TPST-2003 as a potential class-leading therapy for relapsed/refractory multiple myeloma

    60% confidence

  • Tempest plans to present the results of the REDEEM-1 trial and updated results from the IIT at a scientific meeting later this year

    60% confidence

  • Total of 36 patients with relapsed/refractory multiple myeloma had received one infusion of TPST-2003 as of January 31, 2026 data cutoff, including 24 patients in prior Phase 1/2 investigator-initiated trial and 12 patients in ongoing REDEEM-1 trial

    60% confidence

Cited in these Via News reports